Graduate School of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.
Chronic Pain Research Consortium, Duquesne University, Pittsburgh, PA, US.
Theranostics. 2020 Jan 1;10(4):1694-1707. doi: 10.7150/thno.41309. eCollection 2020.
Monocyte derived macrophages (MDMs) infiltrate sites of infection or injury and upregulate cyclooxygenase-2 (COX-2), an enzyme that stimulates prostaglandin-E2 (PgE2). Nanotheranostics combine therapeutic and diagnostic agents into a single nanosystem. In previous studies, we demonstrated that a nanotheranostic strategy, based on theranostic nanoemulsions (NE) loaded with a COX-2 inhibitor (celecoxib, CXB) and equipped with near-infrared fluorescent (NIRF) reporters, can specifically target circulating monocytes and MDMs. The anti-inflammatory and anti-nociceptive effects of such cell-specific COX-2 inhibition lasted several days following Complete Freund's Adjuvant (CFA) or nerve injury in male mice. The overall goal of this study was to investigate the extended (up to 40 days) impact of MDM-targeted COX-2 inhibition and any sex-based differences in treatment response; both of which remain unknown. Our study also evaluates the feasibility and efficacy of a preclinical nanotheranostic strategy for mechanistic investigation of the impact of such sex differences on clinical outcomes. : CFA was administered into the right hind paws of male and female mice. All mice received a single intravenous dose of NIRF labeled CXB loaded NE twelve hours prior to CFA injection. whole body NIRF imaging and mechanical hypersensitivity assays were performed sequentially and NIRF imaging and immunohistopathology of foot pad tissues were performed at the end point of 40 days. : Targeted COX-2 inhibition of MDMs in male and female mice successfully improved mechanical hypersensitivity after CFA injury. However, we observed distinct sex-specific differences in the intensity or longevity of the nociceptive responses. In males, a single dose of CXB-NE administered via tail vein injection produced significant improved mechanical hypersensitivity for 32 days as compared to the drug free NE (DF-NE) (untreated) control group. In females, CXB-NE produced similar, though less prominent and shorter-lived effects, lasting up to 11 days. NIRF imaging confirmed that CXB-NE can be detected up to day 40 in the CFA injected foot pad tissues of both sexes. There were distinct signal distribution trends between males and females, suggesting differences in macrophage infiltration dynamics between the sexes. This may also relate to differences in macrophage turnover rate between the sexes, a possibility that requires further investigation in this model. : For the first time, this study provides unique insight into MDM dynamics and the early as well as longer-term targeted effects and efficacy of a clinically translatable nanotheranostic agent on MDM mediated inflammation. Our data supports the potential of nanotheranostics as presented in elucidating the kinetics, dynamics and sex-based differences in the adaptive or innate immune responses to inflammatory triggers. Taken together, our study findings lead us closer to true personalized, sex-specific pain nanomedicine for a wide range of inflammatory diseases.
单核细胞衍生的巨噬细胞 (MDM) 浸润感染或损伤部位,并上调环氧化酶-2 (COX-2),这是一种刺激前列腺素-E2 (PgE2) 的酶。纳米治疗学将治疗剂和诊断剂结合到单个纳米系统中。在之前的研究中,我们证明了一种基于治疗性纳米乳剂 (NE) 的纳米治疗策略,该乳剂负载有 COX-2 抑制剂 (塞来昔布,CXB),并配备有近红外荧光 (NIRF) 报告器,可特异性靶向循环单核细胞和 MDM。在雄性小鼠中,这种针对循环单核细胞和 MDM 的 COX-2 抑制的抗炎和抗伤害感受作用在完全弗氏佐剂 (CFA) 或神经损伤后持续数天。本研究的总体目标是研究靶向 MDM 的 COX-2 抑制的延长 (长达 40 天) 影响以及治疗反应中的任何性别差异;这些都尚不清楚。我们的研究还评估了一种临床前纳米治疗策略的可行性和疗效,用于机制研究这种性别差异对临床结果的影响。:CFA 被注入雄性和雌性小鼠的右后爪中。所有小鼠在 CFA 注射前 12 小时接受单次静脉注射 NIRF 标记的 CXB 负载的 NE。依次进行全身 NIRF 成像和机械性超敏反应测定,并在 40 天的终点进行足底组织的 NIRF 成像和免疫组织病理学检查。:在雄性和雌性小鼠中,靶向 MDM 的 COX-2 抑制成功改善了 CFA 损伤后的机械性超敏反应。然而,我们观察到疼痛反应的强度或持久性存在明显的性别特异性差异。在雄性小鼠中,与未用药的 NE (DF-NE) (未处理) 对照组相比,通过尾静脉注射给予 CXB-NE 可显著改善机械性超敏反应长达 32 天。在雌性小鼠中,CXB-NE 产生了类似的、尽管不太明显且持续时间较短的作用,最长可达 11 天。NIRF 成像证实,在两性的 CFA 注射足垫组织中,CXB-NE 可在第 40 天检测到。雄性和雌性之间存在明显的信号分布趋势,表明两性之间的巨噬细胞浸润动力学存在差异。这也可能与两性之间的巨噬细胞周转率差异有关,这是该模型中需要进一步研究的一个可能性。:本研究首次提供了关于 MDM 动力学以及临床转化纳米治疗剂对 MDM 介导的炎症的早期和长期靶向作用和疗效的独特见解。我们的数据支持了纳米治疗学的潜力,为阐明对炎症触发因素的适应性或先天免疫反应的动力学、动力学和性别差异提供了依据。综上所述,我们的研究结果使我们更接近于真正的个性化、性别特异性疼痛纳米医学,适用于广泛的炎症性疾病。